PCSK9 Inhibition-A Tale of 2 Potential Treatment Opportunities-Reply
JAMA Cardiol
.
2021 Apr 1;6(4):481.
doi: 10.1001/jamacardio.2020.5613.
Authors
Brian A Bergmark
1
,
Marc S Sabatine
1
2
Affiliations
1
Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
2
Deputy Editor, JAMA Cardiology.
PMID:
33175081
DOI:
10.1001/jamacardio.2020.5613
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
PCSK9 Inhibitors*
Proprotein Convertase 9*
Substances
PCSK9 Inhibitors
PCSK9 protein, human
Proprotein Convertase 9